CBIO Q4 2018 Earnings — Crescent Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

CBIOCrescent Biopharma, Inc.

$337M

Q4 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$68,329

Operating Income

-$15M

Net Income

-$14M

EPS (Diluted)

$-0.32

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$10M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$215M

Total Liabilities

$9M

Stockholders' Equity

$205M

Cash & Equivalents

$210M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$68,329	-$69,565	+1.8%
Operating Income	-$15M	-$10M	-56.9%
Net Income	-$14M	-$9M	-50.2%